Emma Smith1, Damian G Hoy2, Marita Cross1, Theo Vos3, Mohsen Naghavi4, Rachelle Buchbinder5, Anthony D Woolf6, Lyn March1. 1. Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia Department of Rheumatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. 2. School of Population Health, University of Queensland, Herston, Queensland, Australia. 3. School of Population Health, University of Queensland, Herston, Queensland, Australia Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA. 4. Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA. 5. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Malvern, Victoria, Australia Monash Department of Clinical Epidemiology, Cabrini Hospital, Malvern, Victoria, Australia. 6. Department of Rheumatology, Royal Cornwall Hospital, Truro, UK.
Abstract
OBJECTIVE: To estimate disability from the remainder of musculoskeletal (MSK) disorders (categorised as other MSK) not covered by the estimates made specifically for osteoarthritis (OA), rheumatoid arthritis (RA), gout, low back pain and neck pain, as part of the Global Burden of Disease (GBD) 2010 study. METHODS: Systematic reviews were conducted to gather the age-sex-specific epidemiological data for other MSK. The focus was on finding health surveys and published studies that measured the overall amount of MSK disorders and complaints, and classified the remainder of MSK disorders that was not RA, OA, gout, low back or neck pain. Six levels of severity were defined to derive disability weights (DWs) and severity distribution. The data, DWs and severity distribution were used to calculate years of life lived with disability (YLDs). Mortality was estimated for MSK-related deaths classified under other MSK. YLDs were added to years of life lost (YLLs) from the mortality estimates to derive overall burden in disability-adjusted life years (DALYs). RESULTS: Global prevalence of other MSK was 8.4% (95% uncertainty interval (UI) 8.1% to 8.6%). DALYs increased from 20.6 million (95% UI 17.0 to 23.3 million) in 1990 to 30.9 million (95% UI 25.8 to 34.6 million) in 2010. The burden of other MSK increased with age. Globally, other MSK disability burden (YLD) ranked sixth. CONCLUSIONS: Ageing of the global population will further increase the burden of other MSK. Specific MSK conditions within this large category should be considered separately to enable more explicit estimates of their burden in future iterations of GBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To estimate disability from the remainder of musculoskeletal (MSK) disorders (categorised as other MSK) not covered by the estimates made specifically for osteoarthritis (OA), rheumatoid arthritis (RA), gout, low back pain and neck pain, as part of the Global Burden of Disease (GBD) 2010 study. METHODS: Systematic reviews were conducted to gather the age-sex-specific epidemiological data for other MSK. The focus was on finding health surveys and published studies that measured the overall amount of MSK disorders and complaints, and classified the remainder of MSK disorders that was not RA, OA, gout, low back or neck pain. Six levels of severity were defined to derive disability weights (DWs) and severity distribution. The data, DWs and severity distribution were used to calculate years of life lived with disability (YLDs). Mortality was estimated for MSK-related deaths classified under other MSK. YLDs were added to years of life lost (YLLs) from the mortality estimates to derive overall burden in disability-adjusted life years (DALYs). RESULTS: Global prevalence of other MSK was 8.4% (95% uncertainty interval (UI) 8.1% to 8.6%). DALYs increased from 20.6 million (95% UI 17.0 to 23.3 million) in 1990 to 30.9 million (95% UI 25.8 to 34.6 million) in 2010. The burden of other MSK increased with age. Globally, other MSK disability burden (YLD) ranked sixth. CONCLUSIONS: Ageing of the global population will further increase the burden of other MSK. Specific MSK conditions within this large category should be considered separately to enable more explicit estimates of their burden in future iterations of GBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Arthritis; Autoimmune Diseases; Epidemiology; Health Services Research; Outcomes Research
Authors: Jessica Widdifield; Sasha Bernatsky; J Carter Thorne; Claire Bombardier; R Liisa Jaakkimainen; Laura Wing; J Michael Paterson; Noah Ivers; Debra Butt; Anne Lyddiatt; Catherine Hofstetter; Vandana Ahluwalia; Karen Tu Journal: CMAJ Open Date: 2016-05-11
Authors: James Donovan; J David Cassidy; Carol Cancelliere; Erik Poulsen; Mette Jensen Stochkendahl; Jørgen Kilsgaard; Marc-André Blanchette; Jan Hartvigsen Journal: J Can Chiropr Assoc Date: 2015-03
Authors: Iain S Elliott; Reinou S Groen; Thaim B Kamara; Allison Ertl; Laura D Cassidy; Adam L Kushner; Richard A Gosselin Journal: Clin Orthop Relat Res Date: 2014-10-25 Impact factor: 4.176
Authors: Gerson Moreira Damasceno; Arthur Sá Ferreira; Leandro Alberto Calazans Nogueira; Felipe José Jandre Reis; Igor Caio Santana Andrade; Ney Meziat-Filho Journal: Eur Spine J Date: 2018-01-06 Impact factor: 3.134